Genomics of Thrombosis Risk

Study Title: Genomis of Thrombosis Risk

IRB# 16203

CURRENTLY ENROLLING PARTICIPANTS

Thromboembolism is a leading cause of morbidity and mortality in the

United States

. Certain patient groups are known to have a high-risk for recurrent venous thromboembolism (VTE) or arterial thromboembolism (ATE), including patients with cancer and patients with antiphospholipid syndrome. Tremendous benefits will result if individuals at highest risk for developing these thrombotic complications are identified and tailored preventive strategies to minimize the risk for these events are developed.

With the Genomics of Thrombosis Risk study we hope to identify gene expression profiles that predict the risk for recurrent venous thromboembolism in patients with an initial venous thromboembolic event and identify and confirm predictive gene subsets by quantitative RT-PCR to distinguish individuals at low, intermediate, and high risk for recurrent VTE.